By

admin
Exactis is pleased to be working with Dr. Sébastien Perreault from CHU Ste-Justine on the TRAM-01 study, “ Phase 2 study of Trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway”. This study is led by Dr. Sébastien Perreault and the main objective is to determine...
Read More
Our new manuscript “Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition” is now available in Clinical Proteomics. Our research identified potential protein candidates for a blood-based prognostic signature of response to crizotinib in NSCLC patients harboring ALK fusion. https://doi.org/10.1186/s12014-020-9269-6 (Feb 2020) Publication: https://www.exactis.ca/2020/02/07/discovery-of-a-putative-blood-based-protein-signature-associated-with-response-to-alk-tyrosine-kinase-inhibition/
Read More
Dear Exactis Network,  With the current and ever-evolving situation with COVID-19, we wanted to provide you with an update on our response to date and our commitment moving forward. The health, safety and well-being of participants, and our Network Team is a top priority. We are following the lead of Canadian and provincial public health authorities at this time and have been in touch daily...
Read More
Exactis, Discovery, putative blood-based, ALK tyrosine kinase inhibition
Authors: Mathilde Couëtoux du Tertre, Maud Marques, Suzan McNamara, Karen Gambaro, Cyrla Hoffert, Lise Tremblay, Nicole Bouchard, Razvan Diaconescu, Normand Blais, Christian Couture, Vincent Pelsser, Hangjun Wang, Laura McIntosh, Valérie Hindie, Stephane Parent, Laetitia Cortes, Yannick-André Breton, Gwenael Pottiez, Pascal Croteau, Valerie Higenell, Luisa Izzi, Alan Spatz, Victor Cohen, Gerald Batist & Jason Agulnik Abstract...
Read More
Exactis study, Proteogenomics of Colorectal Cancer Liver
Authors: Bernhard Blank-Landeshammer, Vincent R. Richard, Georgia Mitsa, Maud Marques , André LeBlanc, Laxmikanth Kollipara, Ingo Feldmann, Mathilde Couetoux du Tertre, Karen Gambaro , Suzan McNamara, Alan Spatz, René P. Zahedi, Albert Sickmann, Gerald Batist and Christoph H. Borchers Abstract Hotspot testing for activating KRAS mutations is used in precision oncology to select colorectal cancer (CRC) patients who...
Read More
Exactis Innovation is pleased to award $1M CDN to catalyze clinical research on innovative precision oncology therapeutics in Canada. This grant will support a multi-centre clinical trial in the Exactis research network comprising eleven premier cancer care institutions across Canada. The grant is awarded to a research team led by Dr. Helen MacKay (Sunnybrook Health...
Read More
Exactis study
Authors: Mathilde Couetoux du Tertre, Maud Marques, Lise Tremblay, Nicole Bouchard, Razvan Diaconescu, Normand Blais, Christian Couture, Vincent Pelsser, Hangjun Wang, Valerie Higenell, Luisa Izzi, Karen Gambaro, Cyrla Hoffert, Archana Srivastava, Alan Spatz, Caroline Rousseau, Suzan McNamara, Victor Cohen, Gerald Batist and Jason Agulnik Abstract Rearrangements in the anaplastic lymphoma kinase (ALK) gene are found...
Read More
The TRICIA Study, a research project pairing molecular data with artificial intelligence, was awarded funding of $1.6 million this week by the Biopharmaceutical Research Consortium CQDM, the Ministère de l’Économie et de l’Innovation of the Government of Quebec, and the Canadian Cancer Society. Dr. Mark Basik of the Jewish General Hospital, the Principal Investigator of...
Read More
Exactis study, immuno-oncology
Authors: V. Higenell: Exactis InnovationR. Fajzel: Exactis Innovation, Segal Cancer Centre, Sir Mortimer B. Davis Jewish General HospitalG. Batist: Exactis Innovation, Segal Cancer Centre, Jewish General HospitalP. K. CheemaWilliam Osler Health System, University of TorontoH. L. McArthurCedars-Sinai Samuel Oschin Comprehensive Cancer InstituteB. MeloskyBC Cancer Agency Vancouver CentreD. MorrisTom Baker Cancer CentreT. M. PetrellaOdette Cancer Centre,...
Read More
1 2 3 4